查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1715362

藥物研發技術市場（按藥物類型、檢測技術、技術平台、應用和最終用戶分類）—2025-2030 年全球預測

Drug Discovery Technologies Market by Drug Type, Assay Techniques, Technology Platforms, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計 2024 年藥物發現技術市場價值將達到 635 億美元，2025 年將成長至 701.9 億美元，複合年成長率為 10.67%，到 2030 年將達到 1,167.1 億美元。

主要市場統計數據
基準年2024年 635億美元
預計年份：2025年 701.9億美元
預測年份 2030 1167.1億美元
複合年成長率（%） 10.67%

藥物研發已發展成為由先進技術、創新方法和多學科合作編織而成的複雜體系。過去十年，該行業經歷了變革性的變化，利用突破性的技術創新和數位進步來解決識別和開發新療法的複雜問題。在這種動態環境中，傳統方法透過運算工具和高效能平台得到增強，使研究人員能夠簡化從目標識別到臨床前評估的過程。對精確度和效率的不懈追求不僅重新定義了方法論，而且為更多數據主導的藥物開發鋪平了道路。

本執行摘要概述了前沿趨勢、策略性細分、區域動態和影響市場的主要企業。我們捕捉技術進步與市場需求之間的相互作用，並研究新興趨勢將如何影響競爭格局。當揭示藥物發現各環節的層層變化時，我們會發現創新是進步的核心。從學術機構到大型製藥企業的相關人員現在都將受益於這一演變，傳統的邊界將被整合的、技術支援的解決方案所取代。

在精準醫療和個人化治療日益突出的時代，了解這些轉變背後的促進因素至關重要。此次聘任全面審視了重新定義藥物發現結果的策略因素，並為尋求利用這些機會的決策者制定了清晰的藍圖。

塑造現代藥物研發生態系統的變革

近年來，藥物研發生態系統發生了重大轉變。這些變化不僅是漸進的改進，而是對研發方式的根本性重新思考。技術與生物學的融合激發了創新方法，大大提高了藥物發現的效率和精確度。

最大的轉變之一是先進計算模型的整合。現代計算建模平台使研究人員能夠以驚人的精度模擬分子相互作用。此功能可以快速識別有希望的候選藥物，從而減少與實驗檢驗相關的時間和成本。高通量篩檢技術透過快速篩選大量化合物庫來補充這些計算工作，從而加速先導化合物的發現過程。

奈米技術和結構設計也正在徹底改變新療法的概念。這些方法使科學家能夠設計出具有增強特異性和效力的分子，同時限制脫靶效應。將詳細的結構資訊納入藥物設計將有助於制定更明智的方法，從而開發出能夠調節複雜生物系統的高選擇性化合物。

此外，藥物基因組學和個人化醫療的進步開創了標靶治療時代。這種模式轉移優先考慮患者特定因素並確保治療適合個人的基因組成。因此，治療潛力最大化，副作用最小化。數位生物學的進步以及自動化和數據分析的提高使得藥物發現更具預測性。

檢測技術也變得更加可靠，複雜的結合檢測、生化技術、基於細胞的檢測和報導基因分析為化合物行為提供了多維洞察。這些強大的方法提供了關鍵的驗證層，以確保化合物不僅與預期的生物標的相互作用，而且還表現出理想的藥物動力學和動態特性。

隨著行業不斷適應快速變化的情況，這些創新技術的融合正在重新定義行業標準和期望。藥物開發的相關人員擴大採用整體觀點，其中不同技術平台之間的協作和互通性是成功的關鍵。這個不斷發展的框架證明了現代藥物發現的多功能性，使其成為21世紀醫學創新的關鍵。

藥物研發市場的關鍵細分洞察

對藥物發現市場的詳細分析揭示了結構細分，從而提供了對行業營運框架的細緻了解。根據藥物類型進行細分，可以區分生技藥品和小分子藥物，每種藥物都有各自的治療優勢和製造挑戰。生技藥品源自生物體，對複雜疾病具有極佳的治療價值。相較之下，小分子藥物由於其成熟的製造流程和成本效益，傳統上一直是製藥業的主力。

市場區隔進一步分為檢測技術領域。透過結合試驗、生化試驗、基於細胞的試驗和報導基因分析對市場進行了密切研究。這些技術提供了不同層次的洞察，從基本的互動確認到詳細的功能分析。透過將這些方法納入藥物發現過程，可以全面評估先導化合物的藥理特性。

除了檢測技術之外，按技術平台進行細分也成為市場分析的重要方面。計算建模、高性能篩檢、奈米技術、藥物基因體學和基於結構的設計是該領域創新的關鍵驅動力。計算建模加速了早期研究，高通量篩檢有效地縮小了候選化合物的範圍。奈米技術引入了分子級精度，基於結構的設計利用蛋白質和配體的3D構象來增強靶向性。另一方面，藥物基因體學體現了個人化醫療的發展趨勢，它根據個人的基因特徵量身定做治療方案。

此外，藥物發現中基於應用的細分將市場分類為不同的治療和開發階段。綜合方法將生物標記發現與先導化合物發現相結合，並包括臨床前和臨床開發。此外，它還涵蓋目標識別和驗證以及毒性測試。這種多方面的細分可以讓我們仔細檢視藥物開發平臺的每個階段對整體成功率的潛在影響。

最後，最終用戶細分將市場分為學術機構、生技公司和製藥公司。該部門強調，藥物發現是在多樣化的生態系統中運作的。學術機構透過基礎研究和早期發現做出貢獻，生物技術公司以新想法和靈活的策略推動創新，製藥公司利用其大規模營運和臨床專業知識將藥物推向市場。透過相互關聯這些細分觀點，分析框架提供了藥物發現技術的現狀和未來方向的全面圖像。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 慢性病和未滿足的醫療需求增加
      • 擴大使用小分子藥物和生技藥品來治療慢性病和感染疾病
      • 全球CDMO迅速採用藥物研發技術
    • 限制因素
      • 對高開銷和高故障率的擔憂
    • 機會
      • 尖端運算建模和分子模擬平台的開發
      • 基因組學研究和高通量篩檢技術的進展
    • 任務
      • 複雜的監管要求和冗長的核准流程
  • 市場區隔分析
    • 藥物類型：生技藥品在自體免疫疾病和癌症治療中的重要性日益增加
    • 最終用戶：學術機構擴大採用藥物研發技術
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章 藥物研發技術市場（以藥物類型）

  • 介紹
  • 生技藥品
  • 小分子藥物

第7章 藥物發現技術市場（依分析技術）

  • 介紹
  • 結合試驗
  • 生化檢測
  • 基於細胞的檢測
  • 報導基因分析

第8章藥物研發技術市場：技術平台

  • 介紹
  • 計算建模
  • 高效能篩檢
  • 奈米科技
  • 藥物基因組學
  • 基於結構的設計

第9章藥物研發技術市場（依應用）

  • 介紹
  • 生物標記發現
  • 候選人發現
  • 臨床前和臨床開發
  • 目標識別和檢驗
  • 毒理學測試

第 10 章 藥物研發技術市場（依最終用戶）

  • 介紹
  • 學術機構
  • 生技公司
  • 製藥公司

第 11 章：美洲藥物發現技術市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太藥物研發技術市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲藥物研發技術市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abbott Laboratories, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer Healthcare AG
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Bristol-Myers Squibb Company
  • Covaris, LLC
  • Curia Global, Inc.
  • Elucidata Corporation
  • Eurofins Advinus Private Limited
  • Evotec SE
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare Ltd.
  • Gilead Sciences, Inc.
  • Horiba, Ltd.
  • Illumina, Inc.
  • IQVIA Inc.
  • Luminex Corporation by DiaSorin Group
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • PIRAMAL PHARMA LIMITED
  • Randox Laboratories Ltd.
  • Revolution Medicines, Inc.
  • Sanofi SA
  • Sygnature Discovery Limited
  • Syngene International Limited
  • Thermo FIsher Scientific Inc.
  • VWR International LLC
  • WuXi AppTec Co., Ltd.
Product Code: MRR-4348D129FA8B

The Drug Discovery Technologies Market was valued at USD 63.50 billion in 2024 and is projected to grow to USD 70.19 billion in 2025, with a CAGR of 10.67%, reaching USD 116.71 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 63.50 billion
Estimated Year [2025] USD 70.19 billion
Forecast Year [2030] USD 116.71 billion
CAGR (%) 10.67%

Drug discovery has evolved into an intricate tapestry woven with advanced technologies, innovative techniques, and multidisciplinary collaboration. The industry has witnessed a transformative shift over the past decade, leveraging breakthrough innovations and digital advancements to address the complexities of identifying and developing new therapeutics. In this dynamic environment, traditional methods have been augmented with computational tools and high-throughput platforms, enabling researchers to streamline the process from target identification through preclinical evaluation. The relentless pursuit of precision and efficiency has not only redefined methodologies but also paved the way for a more data-driven approach to drug development.

This executive summary outlines the state-of-the-art trends, strategic segmentation, regional dynamics, and key players shaping the market. It captures the interplay between technological advances and market demands, offering insights into how emerging trends are fueling a competitive landscape. As we unravel the layers of change across various segments of drug discovery, it becomes evident that innovation is at the heart of progress. Stakeholders ranging from academic institutions to pharmaceutical giants are now positioned to benefit from this evolution, as traditional boundaries give way to integrated, technology-enabled solutions.

In an era where precision medicine and personalized therapies are becoming increasingly prominent, understanding the drivers behind these transformative shifts is crucial. This introduction sets the stage for a comprehensive exploration of the strategic elements that are redefining outcomes in drug discovery, providing a clear roadmap for decision-makers aiming to harness these opportunities.

Transformative Shifts Shaping the Modern Drug Discovery Ecosystem

Recent years have witnessed profound and transformative changes within the drug discovery ecosystem. These shifts are not merely incremental improvements but represent a fundamental rethinking of how research and development are conducted. The convergence of technology and biology has spurred innovative methodologies that dramatically increase the efficiency and accuracy of drug discovery.

One of the most significant transformations is the integration of advanced computational models. Modern computational modeling platforms enable researchers to simulate molecular interactions with remarkable precision. This capability allows for the rapid identification of promising drug candidates, reducing the time and cost associated with experimental validation. High throughput screening technologies now complement these computational efforts by quickly sifting through vast libraries of compounds, thereby accelerating the lead discovery process.

Nanotechnology and structure-based design are also revolutionizing the way novel therapeutics are conceptualized. These approaches empower scientists to design molecules with enhanced specificity and potency, while reducing off-target effects. Incorporating detailed structural information into drug design facilitates a more informed approach, leading to the development of highly selective compounds capable of modulating complex biological systems.

Moreover, advancements in pharmacogenomics and personalized medicine have ushered in an era of targeted therapies. This paradigm shift prioritizes patient-specific factors, ensuring that treatments are tailored to the individual's genetic makeup. As a result, the therapeutic potential is maximized while adverse effects are minimized. The advances in digital biology, along with increased automation and data analytics, have further enhanced the predictive power of drug discovery efforts.

The reliability of assay techniques has also grown, with refined binding assays, biochemical methods, cell based assays, and reporter gene assays now offering multidimensional insights into compound behavior. These robust methodologies provide a critical layer of validation, ensuring that compounds not only interact with their intended biological targets but also exhibit the desired pharmacokinetic and pharmacodynamic properties.

As the industry continues to adapt to a rapidly changing landscape, the integration of these innovative technologies is redefining industry standards and expectations. Stakeholders in drug development are increasingly adopting a holistic view, where collaboration and interoperability between diverse technological platforms are key drivers of success. This evolving framework is a testament to the versatility of modern drug discovery, positioning it as a cornerstone of medical innovation in the 21st century.

Key Segmentation Insights into the Drug Discovery Market

A detailed analysis of the drug discovery market reveals a structured segmentation that offers a nuanced understanding of the industry's operational framework. At its foundation, segmentation by drug type distinguishes between biologic drugs and small-molecule drugs, each presenting distinct therapeutic advantages and manufacturing challenges. Biologic drugs, which are derived from living organisms, have demonstrated superior efficacy in targeting complex diseases. In contrast, small-molecule drugs have traditionally served as the workhorses of the pharmaceutical industry due to their well-established manufacturing processes and cost-effectiveness.

Further refinement of market segmentation is observed in the realm of assay techniques. The market is meticulously studied through binding assays, biochemical assays, cell based assays, and reporter gene assays. These techniques provide varied levels of insight, from basic interaction confirmation to detailed functional analysis. Integrating these methods into the drug discovery process ensures that lead compounds are evaluated comprehensively for their pharmacological properties.

In addition to assay techniques, segmentation based on technology platforms has emerged as a pivotal aspect of market analysis. Computational modeling, high throughput screening, nanotechnology, pharmacogenomics, and structure based design are the critical drivers of innovation in this space. Each platform offers a unique advantage: computational modeling accelerates early-stage research, while high throughput screening efficiently narrows down candidate compounds. Nanotechnology introduces precision at a molecular scale, and structure based design leverages the three-dimensional conformation of proteins and ligands for enhanced targeting. Pharmacogenomics, meanwhile, embodies the move towards personalized medicine by aligning treatment paradigms with individual genetic profiles.

Moreover, the application-specific segmentation in drug discovery divides the market along different therapeutic and developmental stages. The comprehensive approach considers biomarker discovery alongside lead discovery, while also encompassing preclinical and clinical development. It further extends to target identification and validation, as well as toxicology testing. This multidimensional segmentation ensures that every phase of the drug development pipeline is scrutinized for its potential impact on overall success rates.

Finally, segmentation by end user categorizes the market into academic institutions, biotechnology firms, and pharmaceutical companies. This distinction highlights the diverse ecosystem in which drug discovery operates. Academic institutions contribute through fundamental research and early-stage discoveries, biotechnology firms drive innovation with novel ideas and nimble strategies, and pharmaceutical companies leverage large-scale operations and clinical expertise to bring drugs to market. By interlacing these segmentation perspectives, the analytical framework provides a comprehensive picture of both the current state and future directions of drug discovery technologies.

Based on Drug Type, market is studied across Biologic Drugs and Small-Molecule Drugs.

Based on Assay Techniques, market is studied across Binding Assays, Biochemical Assays, Cell Based Assays, and Reporter Gene Assays.

Based on Technology Platforms, market is studied across Computational Modeling, High Throughput Screening, Nanotechnology, Pharmacogenomics, and Structure Based Design.

Based on Application, market is studied across Biomarker Discovery, Lead Discovery, Preclinical & Clinical Development, Target Identification & Validation, and Toxicology Testing.

Based on End User, market is studied across Academic Institutions, Biotechnology Firms, and Pharmaceutical Companies.

Key Regional Insights Across Global Markets

The regional dynamics in the drug discovery market are as varied as they are significant, with distinct trends observed across major global territories. In the Americas, the market benefits from centralization of research institutions and a robust ecosystem of biotechnology companies and pharmaceutical corporations. The region is known for its high investment in R&D and rapid adoption of technological advancements. This focus is supported by a favorable regulatory environment that encourages innovation while ensuring patient safety. The sustained growth in the Americas is largely attributable to strong government incentives, extensive private funding, and a collaborative environment that marries academic research with industry-led initiatives.

Turning to the Europe, Middle East & Africa region, a blend of rich research heritage and emerging innovation hubs characterizes the landscape. Europe contributes significantly to drug discovery through its well-established infrastructure and rigorous regulatory standards, which foster high-quality research and development. The Middle East & Africa, while representing emerging markets, are increasingly becoming attractive due to their growing investments in healthcare infrastructure and strategic partnerships that aim to integrate global expertise with local talent. The cross-pollination of ideas between established research centers in Europe and the nascent but rapidly evolving markets in the Middle East & Africa creates a dynamic platform for breakthrough innovations and commercialization of novel therapeutics.

In the Asia-Pacific region, an impressive transformation is underway. With a rising number of biotechnology startups and major pharmaceutical companies setting up research facilities, the market in Asia-Pacific is emerging as a crucial hub for drug discovery. The region not only benefits from a large pool of scientific talent but also from cost-effective manufacturing and operational efficiencies. Rapid urbanization, increased healthcare funding, and ongoing initiatives to bolster scientific infrastructure are key drivers fueling the expansion of drug discovery activities in this geography. Additionally, local regulatory reforms and a focus on international collaboration have further solidified Asia-Pacific's role as a significant contributor to global drug innovation.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Pioneering Innovation in Drug Discovery

The landscape of drug discovery is significantly influenced by market leaders who continue to invest in breakthrough technologies and collaborative research. Renowned companies such as Abbott Laboratories, Inc., Amgen Inc., AstraZeneca PLC, Bayer Healthcare AG, and Bio-Rad Laboratories, Inc. have consistently driven innovation by integrating state-of-the-art methodologies in their drug development pipelines. Their commitment to excellence and research integrity has set benchmarks in the field.

Other notable players include bioMerieux SA, Bristol-Myers Squibb Company, Covaris, LLC, Curia Global, Inc., and Elucidata Corporation. These companies are known for their agile approaches to addressing therapeutic challenges and for leveraging multi-disciplinary technologies that bridge traditional and contemporary methods. Eurofins Advinus Private Limited, Evotec SE, F. Hoffmann-La Roche Ltd., and GE Healthcare Ltd. have also made significant contributions with robust research facilities and a strong emphasis on quality assurance.

Gilead Sciences, Inc. and Horiba, Ltd. have been trailblazers in driving targeted therapies and precision medicine, while Illumina, Inc. and IQVIA Inc. have supported the evolution of data-driven approaches in drug discovery. The expertise brought in by Luminex Corporation by DiaSorin Group and Merck & Co., Inc. further underscores the diverse capabilities required to navigate today's competitive market. Additionally, industry giants such as Novartis AG, Pfizer Inc., PIRAMAL PHARMA LIMITED, and Randox Laboratories Ltd. continue to redefine the standards of excellence.

The contributions of Revolution Medicines, Inc., Sanofi S.A., Sygnature Discovery Limited, Syngene International Limited, Thermo Fisher Scientific Inc., VWR International LLC, and WuXi AppTec Co., Ltd. are equally noteworthy. Each of these companies encapsulates the innovative spirit of the drug discovery sector, combining scientific research with commercial insights to develop therapies that address unmet medical needs. Their strategic initiatives not only enhance operational efficiencies but also ensure that cutting-edge technologies translate into tangible patient benefits.

The report delves into recent significant developments in the Drug Discovery Technologies Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Inc., Amgen Inc., AstraZeneca PLC, Bayer Healthcare AG, Bio-Rad Laboratories, Inc., bioMerieux SA, Bristol-Myers Squibb Company, Covaris, LLC, Curia Global, Inc., Elucidata Corporation, Eurofins Advinus Private Limited, Evotec SE, F. Hoffmann-La Roche Ltd., GE Healthcare Ltd., Gilead Sciences, Inc., Horiba, Ltd., Illumina, Inc., IQVIA Inc., Luminex Corporation by DiaSorin Group, Merck & Co., Inc., Novartis AG, Pfizer Inc., PIRAMAL PHARMA LIMITED, Randox Laboratories Ltd., Revolution Medicines, Inc., Sanofi S.A., Sygnature Discovery Limited, Syngene International Limited, Thermo FIsher Scientific Inc., VWR International LLC, and WuXi AppTec Co., Ltd.. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to adopt a multi-pronged approach when navigating the evolving landscape of drug discovery. First and foremost, integrating advanced computational models and high throughput screening should be prioritized. The efficiency gains from these technologies can translate into a swifter transition from ideation to clinical validation while minimizing costs and leveraging data to anticipate outcomes more reliably.

Investment in nanotechnology and structure-based design can substantially elevate the precision of therapeutic candidates. Leaders should consider bolstering R&D efforts by incorporating platforms that allow for molecular-level manipulation and precise targeting. It is prudent to foster cross-disciplinary collaboration between computational scientists, biologists, and chemists to ensure a holistic approach to drug development.

Furthermore, aligning strategies with pharmacogenomics will be instrumental in capturing the full potential of personalized medicine. By integrating genomic data into the decision-making process, companies can tailor treatments to patient-specific profiles, thereby improving efficacy and minimizing adverse effects. Strategic partnerships with academic institutions and biotech innovators can enhance access to critical genetic insights and cutting-edge research tools.

A strong emphasis on robust assay techniques-ranging from binding and biochemical assays to cell based and reporter gene assays-will further refine candidate screening and validation. Industry leaders should continuously update and diversify assay platforms to support the evaluation of compound efficacy comprehensively.

From an operational standpoint, leveraging strategic segmentation insights can streamline the allocation of resources. It is advisable to map investments across various segments including drug type, assay techniques, technology platforms, application areas, and end-user expectations. This methodical segmentation ensures that resources are deployed efficiently while addressing the unique demands of each market segment.

Lastly, a proactive stance on regulatory engagement and market-specific insights will enable companies to stay ahead of compliance challenges. Keeping abreast of regional regulations and leveraging local market dynamics can arm leaders with the competitive advantage necessary to capture growth in emerging markets. A clear strategy that prioritizes innovation, collaboration, and personalization will not only accelerate product development but also secure a sustainable competitive position in the industry.

Conclusion: Strategic Insights for Future Growth

In summary, the evolving landscape of drug discovery is marked by rapid technological advancements, strategic segmentation, and profound regional diversity. This dynamic environment requires industry stakeholders to adopt forward-thinking strategies and agile methodologies to remain competitive. The comprehensive integration of computational tools, advanced screening methods, and personalized medicine is reshaping how therapeutics are discovered and brought to market.

The progressive shift in assay techniques and the embrace of cutting-edge platforms such as nanotechnology and structure-based design have transformed the early stages of drug development. Moreover, a detailed segmentation based on drug type, assay techniques, technology platforms, applications, and end-user demographics offers a granular perspective on market dynamics, facilitating targeted investments and focused research initiatives.

Regional analysis further highlights that while the Americas lead with well-supported research ecosystems, Europe, Middle East & Africa offer a blend of traditional expertise and emerging innovation. The Asia-Pacific region's remarkable growth is underpinned by strategic regulatory reforms, cost efficiencies, and increasing collaborations. Each region presents its distinct set of opportunities and challenges, demanding tailored strategies from market participants.

The role of key industry players remains integral in driving innovation. The combined efforts of established pharmaceutical giants and nimble biotech companies are critical in pushing the boundaries of what is possible in drug discovery. Their continuous investments in R&D, adherence to stringent quality standards, and commitment to patient-centric solutions have laid the foundation for future breakthroughs.

Ultimately, the convergence of technology, segmentation insights, and regional market dynamics underscores the need for a deliberate, innovative, and collaborative approach. Firms that effectively harness these elements are better positioned to manage risks, capitalize on emergent opportunities, and achieve sustained growth in the highly competitive landscape of drug discovery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic diseases and unmet medical needs
      • 5.1.1.2. Growing use of small-molecular and biologics drugs to treat chronic and infectious disorders
      • 5.1.1.3. Rapid adoption of drug discovery technologies by CDMOs worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. High overhead costs & concerns over high failure rate
    • 5.1.3. Opportunities
      • 5.1.3.1. Developing cutting-edge computational modeling and molecular simulation platforms
      • 5.1.3.2. Advancements in genomics research and high-throughput screening technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory requirements and lengthy approval processes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Rising significance of biologic drugs for treating autoimmune disorders and cancer
    • 5.2.2. End User: Expanding adoption of drug discovery technologies within academic institutions
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Drug Discovery Technologies Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Biologic Drugs
  • 6.3. Small-Molecule Drugs

7. Drug Discovery Technologies Market, by Assay Techniques

  • 7.1. Introduction
  • 7.2. Binding Assays
  • 7.3. Biochemical Assays
  • 7.4. Cell Based Assays
  • 7.5. Reporter Gene Assays

8. Drug Discovery Technologies Market, by Technology Platforms

  • 8.1. Introduction
  • 8.2. Computational Modeling
  • 8.3. High Throughput Screening
  • 8.4. Nanotechnology
  • 8.5. Pharmacogenomics
  • 8.6. Structure Based Design

9. Drug Discovery Technologies Market, by Application

  • 9.1. Introduction
  • 9.2. Biomarker Discovery
  • 9.3. Lead Discovery
  • 9.4. Preclinical & Clinical Development
  • 9.5. Target Identification & Validation
  • 9.6. Toxicology Testing

10. Drug Discovery Technologies Market, by End User

  • 10.1. Introduction
  • 10.2. Academic Institutions
  • 10.3. Biotechnology Firms
  • 10.4. Pharmaceutical Companies

11. Americas Drug Discovery Technologies Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Drug Discovery Technologies Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Drug Discovery Technologies Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Novartis secures a full-paid license to leverage Housey Pharma's state-of-the-art drug discovery platform technologies
    • 14.3.2. Vividion Therapeutics acquires Tavros Therapeutics to enhance its genomic screening expertise and drug discovery
    • 14.3.3. AION Labs launched a new startup ProPhet, to enhance small molecule drug discovery
    • 14.3.4. Drug Development Technology player ArisGlobal Completes Acquisition of Amplexor Life Sciences.
    • 14.3.5. Luxna Announces Collaboration Agreement for Drug Discovery Research with Servier
    • 14.3.6. Iktos Raises €15.5M (USD 16.34 million) to Expand AI Drug Discovery Technologies
    • 14.3.7. Charles River Secures USD 50 Million Acquisition of Drug Discovery Tech Company.
    • 14.3.8. BioNTech to Acquire Ai Drug Discovery Start-Up Instadeep for £362m (USD 440.15 Million)
    • 14.3.9. CHARM Launches AI Drug Discovery Technology With USD 50 Million Series A Financing
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories, Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Bayer Healthcare AG
  • 5. Bio-Rad Laboratories, Inc.
  • 6. bioMerieux SA
  • 7. Bristol-Myers Squibb Company
  • 8. Covaris, LLC
  • 9. Curia Global, Inc.
  • 10. Elucidata Corporation
  • 11. Eurofins Advinus Private Limited
  • 12. Evotec SE
  • 13. F. Hoffmann-La Roche Ltd.
  • 14. GE Healthcare Ltd.
  • 15. Gilead Sciences, Inc.
  • 16. Horiba, Ltd.
  • 17. Illumina, Inc.
  • 18. IQVIA Inc.
  • 19. Luminex Corporation by DiaSorin Group
  • 20. Merck & Co., Inc.
  • 21. Novartis AG
  • 22. Pfizer Inc.
  • 23. PIRAMAL PHARMA LIMITED
  • 24. Randox Laboratories Ltd.
  • 25. Revolution Medicines, Inc.
  • 26. Sanofi S.A.
  • 27. Sygnature Discovery Limited
  • 28. Syngene International Limited
  • 29. Thermo FIsher Scientific Inc.
  • 30. VWR International LLC
  • 31. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. DRUG DISCOVERY TECHNOLOGIES MARKET MULTI-CURRENCY
  • FIGURE 2. DRUG DISCOVERY TECHNOLOGIES MARKET MULTI-LANGUAGE
  • FIGURE 3. DRUG DISCOVERY TECHNOLOGIES MARKET RESEARCH PROCESS
  • FIGURE 4. DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. DRUG DISCOVERY TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. DRUG DISCOVERY TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DRUG DISCOVERY TECHNOLOGIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DRUG DISCOVERY TECHNOLOGIES MARKET DYNAMICS
  • TABLE 7. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BINDING ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOCHEMICAL ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY CELL BASED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY REPORTER GENE ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COMPUTATIONAL MODELING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY STRUCTURE BASED DESIGN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PRECLINICAL & CLINICAL DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 240. DRUG DISCOVERY TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 241. DRUG DISCOVERY TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2024